argenx, a global immunology company dedicated to transforming the lives of those living with severe autoimmune diseases, is proud to announce that its Chief Executive Officer, Tim Van Hauwermeiren, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. Don’t miss the opportunity to gain insight into the exciting developments argenx is making in the immunology space at 9:00 a.m. PT.
Experience argenx’s upcoming investor presentation live with a webcast, accessible on the Investors section of the argenx website. After the presentation, a replay of the webcast will be available for 30 days so you don’t miss a single detail.
Argenx is an exciting global immunology company on a mission to improve the lives of those suffering from severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx is pioneering the development of advanced antibody-based medicines to tackle these ailments. The Company has already achieved success with its first-and-only approved neonatal Fc receptor (FcRn) blocker, and is now actively exploring the potential of its other experimental medicines in treating a range of serious autoimmune diseases. With argenx at the helm, the future of autoimmune treatments looks brighter than ever.